Kashiwa Munenobu

カシワムネノブ | Kashiwa Munenobu

Affiliation and department：
Homepage URL (1)： https://www.ritsumei.ac.jp/research/center/cheers/

Research field (1)： Clinical pharmacy

Research theme for competitive and other funds (1)：

Papers (10)：

Munenobu Kashiwa, Miho Tsukada, Ryo Matsushita. Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line Combination Treatment with Chemotherapy for Patients with Extensive-Disease Small-Cell Lung Cancer in Japan. Clinical Drug Investigation. 2024
Munenobu Kashiwa, Hiroyuki Maeda. Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer. Journal of Gastrointestinal Cancer. 2024
Munenobu Kashiwa. Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan. The European journal of health economics : HEPAC : health economics in prevention and care. 2023
Munenobu Kashiwa, Ryo Matsushita. Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer. International Journal of Clinical Pharmacy. 2023
Munenobu Kashiwa, Ryo Matsushita. Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan. Biological & pharmaceutical bulletin. 2022. 45. 7. 895-903

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page